Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Escitalopram
Drug ID BADD_D00809
Description Escitalopram is a selective serotonin re-uptake inhibitor (SSRI) and the S-enantiomer of racemic [citalopram].[A185420] It is used to restore serotonergic function in the treatment of depression and anxiety.[L8513,L8516,L8522] Escitalopram is approximately 150 times more potent than citalopram’s R-enantiomer and is responsible for the vast majority of citalopram’s clinical activity, with some evidence suggesting that the R-enantiomer of racemic citalopram actively dampens the activity of escitalopram rather than existing simply as an inactive enantiomer.[A39738,A185819] Amongst SSRIs, escitalopram exerts the highest degree of selectivity for the serotonin transporter (SERT) relative to other off-targets which may explain its lower rates of adverse effects as compared to other agents in this class.[A185726] Escitalopram also differentiates itself from other SSRIs via allosteric action on its target - this may be the mechanism responsible for its observed superior efficacy and faster onset compared to other SSRIs.[A185825,A185726,A185822]
Indications and Usage Escitalopram is indicated for both acute and maintenance treatment of major depressive disorder (MDD) and for the acute treatment of generalized anxiety disorder (GAD).[L8513] It is additionally indicated for symptomatic relief of obsessive-compulsive disorder (OCD) in Canada.[L8516]
Marketing Status approved
ATC Code N06AB10
DrugBank ID DB01175
KEGG ID D07913
MeSH ID D000089983
PubChem ID 146570
TTD Drug ID D08RBC
NDC Product Code 80425-0320; 50090-4915; 51655-284; 53002-1431; 67296-1200; 0456-2010; 0456-2020; 69097-848; 70518-1785; 71335-1030; 0615-8366; 42708-163; 45865-699; 55700-847; 69844-079; 72189-424; 72189-451; 16729-168; 43547-281; 43547-282; 61919-652; 63187-281; 68001-456; 68071-5248; 68788-7461; 69844-077; 70934-630; 68001-454; 68071-2035; 68645-520; 68788-7510; 69844-078; 70934-957; 71205-344; 71610-425; 71610-534; 72189-449; 16571-755; 16729-170; 50090-2196; 51655-236; 53002-2438; 60760-393; 68788-7912; 70518-2317; 70771-1145; 71335-1002; 71335-1187; 71335-1307; 16571-757; 51655-766; 54838-551; 70518-2430; 70771-1147; 50090-4363; 50090-5312; 50090-6534; 51655-116; 51655-149; 69097-847; 69097-849; 70518-1876; 71205-325; 76282-250; 76282-251; 42708-155; 50090-1930; 70518-2472; 70518-3151; 70771-1146; 82982-030; 43547-280; 50090-6190; 51655-277; 55700-818; 63187-217; 67296-1597; 68001-455; 68645-519; 0456-2005; 70518-1805; 70518-2597; 71335-1571; 72189-438; 0615-8365; 72789-194; 76282-249; 16571-756; 33342-053; 60760-170; 65162-705; 71205-782; 71335-1241; 71335-2058; 0615-8348; 16729-169; 43063-661
UNII 4O4S742ANY
Synonyms Escitalopram | Escitalopram Oxalate | Lexapro
Chemical Information
Molecular Formula C20H21FN2O
CAS Registry Number 128196-01-0
SMILES CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Muscle contracture15.03.05.0240.000028%Not Available
Facial spasm17.04.03.0100.000042%Not Available
Cystitis noninfective20.03.02.001--
Hypophagia19.09.01.004; 14.03.01.006; 07.01.06.010--Not Available
Autism spectrum disorder17.03.05.003; 19.22.02.0020.000038%Not Available
Orthostatic intolerance02.11.01.019; 24.06.01.003; 17.05.01.0070.000038%Not Available
Choroidal effusion06.09.01.0080.000076%Not Available
Lichenoid keratosis23.01.01.004--Not Available
Gastrointestinal inflammation07.08.03.0070.000042%Not Available
Skin haemorrhage24.07.01.103; 23.06.07.0010.000085%Not Available
Procedural pain12.02.05.007; 08.01.08.009--Not Available
Vulvovaginal mycotic infection21.14.02.004; 11.03.05.004--Not Available
Head titubation17.01.06.006--Not Available
Skin abrasion23.03.11.018; 12.01.06.010--Not Available
Post-traumatic pain08.01.08.010; 12.01.08.016--Not Available
Spontaneous haematoma24.07.01.054; 01.01.03.0060.000028%Not Available
Suicidal behaviour19.12.01.0060.000133%Not Available
Substance abuse19.07.06.0180.000070%Not Available
Mixed liver injury09.01.07.0150.000047%Not Available
Activation syndrome19.06.02.008; 17.02.05.0410.000085%Not Available
Liver injury12.01.17.012; 09.01.07.0220.000047%Not Available
Psychiatric decompensation19.01.02.0100.000019%Not Available
Adverse reaction08.06.01.0180.000074%Not Available
Low birth weight baby18.04.02.0030.000028%Not Available
Skin mass23.07.04.014--Not Available
Brain injury19.07.03.007; 17.11.01.0030.000057%Not Available
Anal pruritus07.03.03.002--Not Available
Hypertransaminasaemia09.01.02.0050.000019%Not Available
Anorectal discomfort07.03.03.003--Not Available
Genital hypoaesthesia21.10.05.012; 17.02.06.0280.000076%Not Available
The 32th Page    First    Pre   32 33 34 35 36    Next   Last    Total 36 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene